Prebiotic preferences of human lactobacilli strains in co-culture with bifidobacteria and antimicrobial activity against <i>Clostridium difficile</i>

Ambalam, Padma; Kondepudi, Kanthi Kiran; Balusupati, Praveen Babu; Nilsson, Ingrid; Wadström, Torkel; Ljungh, Åsa

doi:10.1111/jam.12953

Cited by 25 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results point out at B. longum IPLA20022 and B. breve IPLA20006, and the prebiotics Synergy and Actilight, as the most promising alternatives for inhibiting the growth of C. difficile . Moreover, they suggest that the pathogen inhibition is strain and substrate specific, which is in agreement with previous reports (Kondepudi et al, 2012 ; Tejero-Sariñena et al, 2013 ; Ambalam et al, 2015 ). Interestingly, the growth of C. difficile was significantly increased ( p < 0.05) by B. breve in the presence of Inulin, indicating a potential risk of such combination and underlining the importance of a careful strain and substrate specific assessment.…”

Section: Resultssupporting

confidence: 92%

“…CDI is treated with antibiotics but a high rate of recurrence is present. In this context, new therapeutic alternatives for treating or preventing CDI are being continuously explored, among them the inhibition of C. difficile growth by the use of probiotics or prebiotics has been tested (Ambalam et al, 2015 ; Auclair et al, 2015 ; Forssten et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

“…However, other potential targets of probiotics and prebiotics on CDI, such as their impact on toxin production by the pathogen, and/or toxin activity, have been explored to a lesser extent and have not attracted attention until recently (Kondepudi et al, 2014 ; Yun et al, 2014 ; Andersen et al, 2015 ). Ambalam et al ( 2015 ) recently reported the ability of cell-free supernatants from some Lactobacillus strains, and a probiotic mix, to inhibit the growth of C. difficile strains in variable way depending on the carbon source used. Moreover, the authors observed a reduction of toxin titers in those C. difficile cultures with inhibitory cell-free supernatants added.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates

et al. 2016

View full text Add to dashboard Cite

The intestinal overgrowth of Clostridium difficile, often after disturbance of the gut microbiota by antibiotic treatment, leads to C. difficile infection (CDI) which manifestation ranges from mild diarrhea to life-threatening conditions. The increasing CDI incidence, not only in compromised subjects but also in traditionally considered low-risk populations, together with the frequent relapses of the disease, has attracted the interest for prevention/therapeutic options. Among these, probiotics, prebiotics, or synbiotics constitute a promising approach. In this study we determined the potential of selected Bifidobacterium strains for the inhibition of C. difficile growth and toxicity in different carbon sources. We conducted co-cultures of the toxigenic strain C. difficile LMG21717 with four Bifidobacterium strains (Bifidobacterium longum IPLA20022, Bifidobacterium breve IPLA20006, Bifidobacterium bifidum IPLA20015, and Bifidobacterium animalis subsp. lactis Bb12) in the presence of various prebiotic substrates (Inulin, Synergy, and Actilight) or glucose, and compared the results with those obtained for the corresponding mono-cultures. C. difficile and bifidobacteria levels were quantified by qPCR; the pH and the production of short chain fatty acids was also determined. Moreover, supernatants of the cultures were collected to evaluate their toxicity using a recently developed model. Results showed that co-culture with B. longum IPLA20022 and B. breve IPLA20006 in the presence of short-chain fructooligosaccharides, but not of Inulin, as carbon source significantly reduced the growth of the pathogen. With the sole exception of B. animalis Bb12, whose growth was enhanced, the presence of C. difficile did not show major effects upon the growth of the bifidobacteria. In accordance with the growth data, B. longum and B. breve were the strains showing higher reduction in the toxicity of the co-culture supernatants.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates

et al. 2016

View full text Add to dashboard Cite

show abstract

“…breve produces compounds that enhance the growth of non-amylolytic L . paracasei [43]. In return, lactobacilli ferment monosaccharides to produce 1,4-dyhydroxi-2-naphtoic acid with potent bifidogenic effects on B .…”

Section: Probiotics and The Modulation Of The Gut Immune Responsementioning

confidence: 99%

The Impact of Lactoferrin on the Growth of Intestinal Inhabitant Bacteria

Vega-Bautista

Garza

Carrero

et al. 2019

IJMS

View full text Add to dashboard Cite

Lactoferrin (Lf) is an iron-binding milk glycoprotein that promotes the growth of selected probiotic strains. The effect of Lf on the growth and diversification of intestinal microbiota may have an impact on several issues, including (i) strengthening the permeability of the epithelial cell monolayer, (ii) favoring the microbial antagonism that discourages the colonization and proliferation of enteric pathogens, (iii) enhancing the growth and maturation of cell-monolayer components and gut nerve fibers, and (iv) providing signals to balance the anti- and pro-inflammatory responses resulting in gut homeostasis. Given the beneficial role of probiotics, this contribution aims to review the current properties of bovine and human Lf and their derivatives in in vitro probiotic growth and Lf interplay with microbiota described in the piglet model. By using Lf as a component in pharmacological products, we may enable novel strategies that promote probiotic growth while conferring antimicrobial activity against multidrug-resistant microorganisms that cause life-threatening diseases, especially in neonates.

show abstract

“…Several strains of Lactobacillus acidophilus have proven to shorten hospitalisation of children with diarrhoea, reduce serum cholesterol, be effective as adjuvant therapy for bacterial vaginosis, and exhibit important immunomodulatory effects [ 17 , 18 , 19 , 20 ]. Different strains of Bifidobacterium lactis have effectively decreased symptoms of irritable bowel syndrome, constipation, dental plague, periodontopathogens and exhibited antimicrobial activity [ 21 , 22 , 23 ]. Bacillus coagulans GBI-30 is successful in reducing daily bowel movements in patients with irritable bowel syndrome [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Study of the In Vitro Antagonistic Activity of Various Single-Strain and Multi-Strain Probiotics against Escherichia coli

Fijan

Šulc

Steyer

2018

IJERPH

View full text Add to dashboard Cite

Escherichia coli is an important commensal of our gut, however, many pathogenic strains exist, causing various severe infections in the gut or beyond. Due to several antibiotic resistance patterns of E. coli, research of alternative treatments or adjuvant therapy is important. One of these is the use of probiotics as antagonistic agents against E. coli. Most published studies investigate only one strain of E. coli and single-strain probiotics. The objectives of this study were to evaluate the antagonistic activity of selected single-strain and multi-strain probiotic supplements against selected clinical E. coli pathotypes using the in vitro agar spot test and the co-culturing method. Molecular methods were used to determine the presence of the genus lactobacilli and bifidobacteria as well as certain selected strains in the probiotic supplements. The agar-spot test showed that the multi-strain probiotics were more effective than the single-strain probiotics. On the other hand, the co-culturing method showed the opposite result, indicating that results are importantly influenced by the chosen method. The most effective single-strain probiotics against E. coli strains were Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus reuteri DSM 17938. The most effective multi-strain probiotics contained lactobacilli, bifidobacteria and enterococci strains, thus proving that most effective probiotics against E. coli strains are the lactic acid bacteria and bifidobacteria. The overall results from both in vitro tests reveal that all selected probiotics exhibited an antagonistic activity against all E. coli strains. From a public health perspective probiotics have thus proved to be successful in inhibiting the growth of E. coli and could therefore be used as adjuvant therapy or alternative therapy in E. coli infections.

show abstract

Prebiotic preferences of human lactobacilli strains in co-culture with bifidobacteria and antimicrobial activity against Clostridium difficile

Abstract: Results are promising for the development of a multi-strain synergistic synbiotic supplement for protection against Cl. difficile infection.

Cited by 25 publications

References 44 publications

Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates

Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates

The Impact of Lactoferrin on the Growth of Intestinal Inhabitant Bacteria

Study of the In Vitro Antagonistic Activity of Various Single-Strain and Multi-Strain Probiotics against Escherichia coli

Contact Info

Product

Resources

About